ST. LOUIS -- An outbreak of 72 cases of monkeypox in the United States during the summer of 2003 didn't produce a single fatality, even though the disease usually kills 10 percent of those infected. Why did none of the patients die? New research from Saint Louis University Health Sciences Center and several partner institutions may provide
an answer.
In this month's issue of Virology, researcher and senior author Mark Buller, PhD, from Saint Louis University Health Sciences Center and colleagues conclude that some strains of monkeypox are more virulent than others, depending on where in Africa the virus came from.
"We have at least two biological strains of monkeypox virus -- one on the west coast of Africa, and the other in the Congo basin," Buller said. "The 2003 outbreak in the United States was from West Africa. If it had come from Congo, we might have had a bigger problem on our hands and very well might have seen patient deaths."
Researchers from the University of Victoria, Washington University School of Medicine, U.S. Army Research Institute of Infectious Diseases, the University of Alabama, East Carolina University and the Centers for Disease Control and Prevention are co-authors of the research.
Buller said that recent studies suggest the incidence of monkeypox is increasing due to encroachment of human into habitats of animal reservoirs. Monkeypox is classified as a "zoonosis," which means that it is a disease of animals that can be transmitted to humans under natural conditions. The first cases of monkeypox reported in humans involved contact between humans and animals in Africa.
The first outbreak of monkeypox in the Western hemisphere occurred in the U.S. Midwest from April to June of 2003. The virus entered the U.S. in a shipment of African rodents from Ghana in West Africa destined for the pet trade. At a pet distribution center, prairie dogs became infected and were responsible for 72 confirmed or suspected cases of human monkeypox.
"Unlike African outbreaks, the U.S. outbreak resulted in no fatalities and there was no documented human-to-human transmission," Buller said.
Monkeypox is part of a family of viruses that cause human smallpox, cowpox, and camelpox as well as monkeypox. Monkeypox usually produces a less severe illness with fewer fatalities than smallpox. But its symptoms are similar: fever, pus-filled blisters all over the body, and respiratory problems.
"Our finding may explain the lack of case-fatalities in the 2003 monkeypox outbreak in the United States, which was caused by a West African virus," Buller said.
The research was funded in part by grants from the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases and the National Institutes of Health to The Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research.
Source: Saint Louis University Health Sciences Center
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.